This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor:
We should like to make a few critical comments on Dr. Thomas Acers' article, "Toxoplasmic Retinochoroiditis: A Double Blind Therapeutic Study" (Arch Ophthal 71:58-62, 1964).First of all, we believe his selection of cases is somewhat at fault. The author himself says: "No distinction is made as to the severity of the inflammatory process, anatomical site of the lesion, duration, or frequency of occurrences." In comparing the efficacy of two medical regimens it seems to us that it is essential to make the two groups of patients as nearly parallel as possible; ie, one should endeavor to have equal numbers of patients with acute exudative lesions, subsiding peripheral lesions, etc, in both groups. This is particularly true when the lengths of time required for subsidence of the inflammation are compared. It might well be that a case of retinitis in the subsiding phase could be expected to
O'Connor GR, Remington JS. THERAPY OF TOXOPLASMIC RETINOCHOROIDITIS. Arch Ophthalmol. 1964;71(6):883–884. doi:10.1001/archopht.1964.00970010899023
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: